Comparative clinicopathological and outcome analysis of differentiated thyroid cancer in Saudi patients aged below 60 years and above 60 years.
BACKGROUND
The aim of this study was to evaluate the treatment outcomes of differentiated thyroid cancer in Saudi patients aged above 60 years.


METHODS
Comparative analysis was performed in 252 patients aged 46-60 years (Group A) and 118 patients aged above 60 years (Group B), who had thyroidectomy, radioactive iodine-131, and thyroid-stimulating hormone suppression therapy between July 2000 and December 2012. Different clinicopathological features, treatment, complications, disease-free survival, and overall survival rates were compared.


RESULTS
Mean age of patients in Group A was 51.9 years (range: 46-60), and mean age of those in Group B was 68.6 years (range: 62-97). Group B patients had higher positive lymph nodes (43.2%), P=0.011. The frequency of extrathyroidal extension, multifocality, and lymphovascular space invasion was seen more in Group B than in Group A. Postsurgical complications (permanent hypoparathyroidism, bleeding, and wound infections) were also seen more in Group B (P=0.043, P=0.011, and P=0.021, respectively). Group B patients experienced more locoregional recurrences (11.0%, P=0.025); similarly, more distant metastases were observed in Group B (15.3%, P=0.003). The 10-year disease-free survival rates were 87.6% in Group A and 70.8% in Group B (P<0.0001).


CONCLUSIONS
Differentiated thyroid cancer in patients aged above 60 years are more aggressive biologically and associated with a worse prognosis, and the morbidity is significantly high as compared to patients aged below 60 years.
Department of Otolaryngology- Head & Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Khalid Hussain
KH
Al-Qahtani
Department of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Mutahir A
MA
Tunio
Department of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Mushabbab Al
MA
Asiri
Department of Radiation Oncology, NCI, Cairo University, Cairo, Egypt.
Yasser
Y
Bayoumi
Department of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Ali
A
Balbaid
Department of Endocrinology and Thyroid Oncology.
Naji J
NJ
Aljohani
Histopathology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Hanadi
H
Fatani
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005507:Food Contamination, Radioactive; D006801:Humans; D006996:Hypocalcemia; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D019106:Postoperative Hemorrhage; D012189:Retrospective Studies; D012529:Saudi Arabia; D013964:Thyroid Neoplasms / Q000145:classification / Q000628:therapy*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D013972:Thyrotropin
aged above 60 years; aged below 60 years; clinicopathological characteristics; comparative analysis; differentiated thyroid cancers; elderly patients; patients aged above 45 years; treatment outcomes